Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096482 | 0.90 | MAPT (0.73) | MAPTKDM4EDRD2DRD4NPC1 | |
| SCHEMBL5776193 | 0.88 | MAPT (0.67) | MAPTKDM4EDRD2DRD4NPC1 | |
| SCHEMBL11808846 | 0.86 | MAPT (0.50) | MAPTKDM4EDRD2DRD4NPC1 | |
| SCHEMBL2638095 | 0.84 | KDM4E (0.81) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| SCHEMBL29530477 | 0.84 | KDM4E (0.81) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| SCHEMBL29779540 | 0.82 | KDM4E (0.58) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL698487 | 0.82 | KDM4E (0.78) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| SCHEMBL4051485 | 0.82 | KDM4E (0.58) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| SCHEMBL288320 | 0.81 | MAPT (0.54) | MAPTKDM4EDRD2DRD4ALDH1A1 | |
| SCHEMBL8511891 | 0.81 | KDM4E (0.54) | MAPTKDM4EDRD2DRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039135-A | Carboxyl chalcone derivative and preparation method and application thereof | 四川大学 | 2024-11-29 | — | — | CN | claimed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-115353478-A | Preparation method of indole compound | 南京工业大学 | 2022-11-18 | — | — | CN | claimed |
| CN-119039135-A | Carboxyl chalcone derivative and preparation method and application thereof | 四川大学 | 2024-11-29 | — | — | CN | disclosed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115353478-B | Preparation method of indole compound | 南京工业大学 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023125473-A1 | INDOLINE COMPOUNDS AND DERIVATIVES THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国药科大学 | 2023-07-06 | — | — | WO | disclosed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | disclosed |
| CN-115353478-A | Preparation method of indole compound | 南京工业大学 | 2022-11-18 | — | — | CN | disclosed |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3468965-B1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | LILLY CO ELI (US) | 2020-04-29 | — | — | EP | disclosed |
| US-6004957-A | VIRICIDES FOR HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-12-21 | — | — | US | disclosed |
| US-5977137-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0659181-B1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMA (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5856353-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0885887-A2 | Sulfonamide inhibitors of HIV-Aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5783701-A | ANTI-HIV VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-07-21 | — | — | US | disclosed |
| US-5585397-A | VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | MCL1, FOXM1, IDO1 | MAPT 3015/4885KDM4E 1736/4885DRD2 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.